HPLC-MS/MS based pharmacokinetic study of alkaloids of sinomenium acutum

Abstract

Abstract:

AIM: To establish a LC-MS/MS method for the study of pharmacokintic characteristics of alkaloids of sinomenium acutum in sprague dawley rat, and lay the foundation for the extensive research and clinical use of sinomenium acutum. METHODS: (1)LC-MS/MS method for the quantification of alkaloids of sinomenium acutum in biological sample was developed. (2)The in vivo time course of sinomenium acutum extracts (10 g crude drug/kg) in rats after a single oral administration was investigated. Pharmacokinetic parameters were calculated from the concentration data determined by LC-MS/MS. RESULTS:The standard curves showed good linearity over the concentration range of sinoacutine (13.8-3 530.0 ng/mL, R²=0.999 9) and magnoflorine (5.8-2 960.0 ng/mL, R²=0.999 8) in rat plasma. The inter-day and intra-day precision and accuracy values of sinoacutine and magnoflorine at three levels of QC samples were less than 15%. Pharmacokinetic study in rats showed that the main parameters for sinoacutine and magnoflorine were Cmax (14.88) and (0.99) μg/mL, Tmax (55.00) and (57.50) min, T1/2 (2.64) and (6.08) h, AUMC(0-t) (369 127.25) and (32 143.44) μg·h·h·mL-1, AUC(0-t) (2 482.76) and (177.77) μg·h·mL-1, MRT(0-t) (2.50) and (3.12) h, respectively. CONCLUSION: A sensitive, specific, and suitable LC-MS/MS method is validated for simultaneously quantifying the concentrations of sinoacutine and magnoflorine in rat plasma. Pharmacokinetic parameters show that the alkaloids of sinomenium acutum in rats conform to the non-compartmental model, and the plasma concentration reaches its peak rapidly, the elimination process is slow with high blood concentration.

Key words: alkaloids of sinomenium acutum, LC-MS/MS, pharmacokinetics

CLC Number:

R965.2

XIE Tong, CHENG Xuefang. HPLC-MS/MS based pharmacokinetic study of alkaloids of sinomenium acutum[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 984-991.

References

［1］国家中医药管理局《中华本草》编委会. 中华草本［M］. 上海：上海科学技术出版社, 1999: 1966-1968.
［2］江苏新医学院. 中药大辞典（上册）［M］. 上海：上海科学技术出版社, 1982: 1234.
［3］曹吉慧, 赵桂森, 冯延江. 青风藤的化学成分与药理作用［J］. 国外医药(植物药分册), 2008, 23(2): 62-66.
［4］Min YD, Choi SU, Lee KR. Aporphine alkaloids and their reversal activity of multidrug resistance (MDR) from the stems and rhizomes of Sinomenium acutum［J］. Arch Pharm Res, 2006, 29(8): 627-632.
［5］黄筑艳, 张援虎, 周岚, 等. 青风藤化学成分的研究(Ⅱ)［J］. 时珍国医医药, 2008,40(8): 193-196.
［6］牟慧, 蔡辉. 青藤碱在类风湿关节炎中的作用［J］. 山西医药杂志, 2012, 41(11): 1114-1115.
［7］张欣悦, 高永翔. 青藤碱的免疫抑制和抗炎活性研究进展［J］. 湖南中医杂志, 2016, 32(3): 193-194,199.
［8］Wang Q, Li XK. Immunosuppressive and anti-inflammatory activities of sinomenine［J］. Int Immunopharmacol, 2011, 11(3): 373-376.
［9］马云淑, 淤泽溥, 赵子仙, 等. 青风藤碱的镇痛镇静作用［J］. 云南中医学院学报, 1992, 32(4): 9-11.
［10］黎炼, 罗志刚. 青藤碱的免疫抑制作用机制的研究进展［J］. 中南医学科学杂志, 2015, 5(1): 86-89.
［11］Zhao Y, Li J, Yu K, et al. Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B［J］. Int Immunopharmacol, 2007, 7(5): 637-645.
［12］谢守霞, 金其泉. 青风藤碱对心脏作用的研究进展--兼论再灌注心律失常［J］. 蚌埠医学院学报, 1989, 14(3): 207-209.
［13］张群燕, 赵智明, 姚茹冰, 等. 青藤碱抑制类风湿关节炎滑膜细胞增殖与诱导凋亡的研究［J］. 中华中医药学刊, 2017, 36(1): 53-55.
［14］高晨鑫, 张湛明, 陈继红, 等. 青藤碱对类风湿关节炎细胞因子影响的研究进展［J］. 风湿病与关节炎, 2017, 6(2): 72-75.
［15］张斯汉, 周远大, 何海霞. 青藤碱在家兔体内的药代动力学研究［J］. 重庆医科大学学报, 2008, 33(7): 868-870.
［16］Long LH, Wu PF, Chen XL, et al. HPLC and LC-MS analysis of sinomenine and its application in pharmacokinetic studies in rats［J］. Acta Pharmacol Sin, 2010, 31(11): 1508-1514.
［17］Zhang MF, Zhao Y, Jiang KY, et al. Comparative pharmacokinetics study of sinomenine in rats after oral administration of sinomenine monomer and Sinomenium acutum extract［J］. Molecules, 2014, 19(8): 12065-12077.
［18］申汉元, 郝海平, 王广基. 中药注射剂药物代谢动力学研究现状［J］. 中国临床药理学与治疗学, 2014, 19(8): 937-942.
［19］谢元超, 祝清芬, 范治云, 等. RP-HPLC测定盐酸青藤碱不同给药途径的血药浓度及药动学研究［J］. 中国药学杂志, 2005, 40(1): 59-60.
［20］马廷升, 李高, 刘志华, 等. 盐酸青藤碱不同晶形在人体的相对生物利用度研究［J］. 中国药业, 2006, 15(12): 3-4.
［21］李凡, 郝保华, 李伟泽, 等. 电致孔条件下巴布剂中青藤碱透皮吸收的药动学研究［J］. 第二军医大学学报, 2008, 29(9): 1096-1098.
［22］邓艳平, 肖衍宇, 平其能, 等. 盐酸青藤碱缓释组合微丸的体内外相关性研究［J］. 福建医科大学学报, 2011, 45(3): 172-176.
［23］Liu ZQ, Chan K, Zhou H, et al. The pharmacokinetics and tissue distribution of sinomenine in rats and its protein binding ability in vitro［J］. Life Sci, 2005, 77(25): 3197-3209.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[14]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[15]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.